Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 15/2013

01-10-2013 | Editorial

Targeting Hyperglycaemia with Anti-Obesity Drugs: Time for a Paradigm Shift?

Authors: Andrew J. Krentz, Marcus Hompesch

Published in: Drugs | Issue 15/2013

Login to get access

Excerpt

Excess adiposity, arising from a chronic imbalance of energy intake relative to expenditure, is regarded as a hallmark of type 2 diabetes. It is well established that whole-body insulin resistance results from the acquisition of surplus adipose tissue mass. In turn, insulin resistance is implicated in the deleterious cardiometabolic profile that is characteristic of type 2 diabetes [1]. Voluntary decreases in body fat mass lead to improvements in carbohydrate and lipid metabolism together with reductions in blood pressure and markers of inflammation [1, 2]. Accordingly, current international treatment guidelines for type 2 diabetes advocate reducing hyperglycemia using non-pharmacological means wherever possible [3, 4]. …
Literature
1.
Klein S, Sheard NF, Pi-Sunyer X, et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care. 2004;27:2067–73.PubMedCrossRef
2.
3.
4.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.PubMedCrossRef
5.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19:327–36.PubMed
6.
Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.PubMedCrossRef
7.
Jacob S, Rabbia M, Meier MK, Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab. 2009;11:361–71.PubMedCrossRef
8.
Vettor R, Serra R, Fabris R, Pagano C, Federspil G. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care. 2005;28:942–9.PubMedCrossRef
9.
Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006;368:1660–72.PubMedCrossRef
10.
Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–52.PubMedCrossRef
11.
Astrup AV, Oppert J-M, Peterson CA. Weight loss and improvements in cardiometabolic outcomes with extended-release phentermine/topiramate treatment in overweight/obese subjects with type 2 diabetes. Diabetologia 2012;55(suppl 1):S48.
12.
13.
Nigro SC, Luon D, Baker WL. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity. Curr Med Res Opin. 2013;29:839–48.
14.
Hoy SM. Lorcaserin: a review of its use in chronic weight management. Drugs. 2013;73(5):463–73.
15.
Bai B, Wang Y. The use of lorcaserin in the management of obesity: a critical appraisal. Drug Des Dev Ther. 2010;5:1–7.
16.
Gallwitz B. Novel oral anti-obesity agents: new perspectives with lorcaserin? Drugs. 2013;73:393–5.PubMedCrossRef
17.
O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426–36.PubMedCrossRef
18.
19.
Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity. 2009;17:494–503.PubMedCrossRef
20.
Chan EW, He Y, Chui CS, Wong AY, Lau WC, Wong IC. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev. 2013;14(5):383–92.
21.
22.
Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs: insights from the rosiglitazone experience. N Engl J Med. Epub 2 Sep 2013
23.
Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540–59.PubMedCrossRef
24.
Raz I, Riddle MC, Rosenstock J, et al. Personalized management of hyperglycemia in type 2 diabetes: reflections from a diabetes care editors’ expert forum. Diabetes Care. 2013;36:1779–88.PubMedCrossRef
Metadata
Title
Targeting Hyperglycaemia with Anti-Obesity Drugs: Time for a Paradigm Shift?
Authors
Andrew J. Krentz
Marcus Hompesch
Publication date
01-10-2013
Publisher
Springer International Publishing
Published in
Drugs / Issue 15/2013
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-013-0123-2

Other articles of this Issue 15/2013

Drugs 15/2013 Go to the issue

Leading Article

β-Adrenoceptor Modulation in Chronic Obstructive Pulmonary Disease: Present and Future Perspectives

Review Article

Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties

Systematic Review

A Systematic Review of Pharmacological Pain Management in Multiple Sclerosis

Adis Drug Evaluation

Fidaxomicin: A Review of Its Use in Patients with Clostridium difficile Infection

Adis Drug Evaluation

Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer

Therapy in Practice

Optimal Sequencing of Anti-HER2 Therapy Throughout the Continuum of HER2-Positive Breast Cancer: Evidence and Clinical Considerations